Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2024

Rhea-AI Summary

Amphastar Pharmaceuticals reported net revenues of $171.8 million for the three months ended March 31, 2024. The company achieved GAAP net income of $43.2 million and adjusted non-GAAP net income of $55.3 million. Notable highlights include BAQSIMI revenue growth of 22% over the first quarter of 2023. The company experienced positive sales increases in several key products like Glucagon, Epinephrine, and Primatene MIST ®. However, there were decreases in sales of Lidocaine, Enoxaparin, and Naloxone. The company's gross profit margin was 52.4% of net revenues, driven by factors like increased sales of higher-margin products. Amphastar's financial performance demonstrates a strong first quarter with promising growth potential.

Positive

• Net revenues reached $171.8 million for the first quarter, showcasing strong performance.

• BAQSIMI revenue growth of 22% indicates promising potential for continued growth.

• Gross profit margin of 52.4% reflects effective management of costs and higher-margin product sales.

• Successful sales increases in key products like Glucagon, Epinephrine, and Primatene MIST ® demonstrate market demand and growth opportunities.

• Adjusted non-GAAP net income of $55.3 million signifies a profitable quarter for Amphastar Pharmaceuticals.

Negative

• Decreases in sales of products like Lidocaine, Enoxaparin, and Naloxone impacted overall net revenues.

• API sales decreased due to timing of customer purchases, affecting total net revenues for the quarter.

• Research and development expenses decreased, potentially impacting future product development and innovation.

Insights

Pharmaceutical & Biotech Financial Analyst

Amphastar Pharmaceuticals' reported revenue growth is notable, especially a 22%> rise in BAQSIMI^® sales compared to the previous year. This increase is significant given that pharmaceutical sales growth rates are generally more modest. The report indicates that Amphastar is potentially positioning itself for further growth, particularly with the successful transition of BAQSIMI^® sales in-house. It’s also important to note that the growth in Epinephrine and Phytonadione sales was due to supplier shortages, indicating possibly temporary conditions that boosted Amphastar's sales. However, investors should consider the decline in sales of Enoxaparin and Naloxone, which suggests challenges in these segments. Furthermore, the increase in depreciation and amortization expenses is a factor of the BAQSIMI^® assets acquisition, impacting cost structure. To summarize, the strong financial performance, particularly in revenue growth and net income, suggests operational efficiency and could potentially lead to positive stock performance in the short term.

Market Research Analyst

Focusing on Amphastar Pharmaceuticals' pipeline, the mention of four ANDAs, three biosimilar products in development and four generic products targeting markets with substantial sizes indicates an aggressive pipeline strategy. Investors should recognize the significance of a healthy pipeline in the pharmaceutical industry as it represents future revenue streams and growth opportunities. The advancements toward markets with over $3 billion> and $7 billion> in size is particularly promising for future earnings potential. Additionally, the diversification of the pipeline into various dosage forms, like injectable and intranasal, is a strategic move given the increasing demand for user-friendly administration routes. The long-term effect of these developments is contingent on successful FDA approvals and market adoption. It’s important to monitor the regulatory landscape and market competition as they will influence Amphastar's ability to capitalize on these opportunities.

Healthcare Industry Analyst

Amphastar’s report showcases a strategic utilization of its subsidiary, ANP, to bolster its active pharmaceutical ingredient (API) offerings. This is an intelligent move as vertical integration in pharmaceutical manufacturing can lead to cost efficiencies and a more controlled supply chain, which is vital in the face of global API shortages and geopolitical instabilities. The reported decrease in API sales due to timing issues should be carefully watched by investors as it may indicate larger market dynamics at play that could influence future revenues and margins. Additionally, increased labor costs and component pricing can be attributed to broader economic factors and could impact profit margins if they continue to rise. It's essential to consider how these industry-wide trends might affect Amphastar's operational costs and pricing strategies moving forward.

Reports Net Revenues of $171.8 Million for the Three Months Ended March 31, 2024

RANCHO CUCAMONGA, CA / ACCESSWIRE / May 8, 2024 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) ("Amphastar" or the "Company") today reported results for the three months ended March 31, 2024.

First Quarter Highlights

• Net revenues of $171.8 million for the first quarter
• GAAP net income of $43.2 million, or $0.81 per share, for the first quarter
• Adjusted non-GAAP net income of $55.3 million, or $1.04 per share, for the first quarter

Dr. Jack Zhang, Amphastar's President and Chief Executive Officer, commented: "Amphastar's strong first quarter results were led by BAQSIMI ^® revenue growth of 22% over what Eli Lilly & Company ("Lilly") reported for the first quarter of 2023. This significant increase demonstrates a strong transition and the potential for continued growth of BAQSIMI ^® ."

		Three Months Ended
		March 31,
		2024				2023
		(in thousands, except per share data)
Net revenues		$	171,836			$	140,022
GAAP net income		$	43,177			$	26,032
Adjusted non-GAAP net income*		$	55,296			$	32,143
GAAP diluted EPS		$	0.81			$	0.50
Adjusted non-GAAP diluted EPS*		$	1.04			$	0.62

____________________________________

* Adjusted non-GAAP net income and adjusted non-GAAP diluted EPS are non-GAAP financial measures. Please see the discussion in the section entitled "Non-GAAP Financial Measures" and the reconciliation of GAAP to non-GAAP financial measures in Table III of this press release.

First Quarter Results

		Three Months Ended
		March 31,								Change
		2024				2023				Dollars				%
						(in thousands)
Product revenues:
Glucagon		$	28,535			$	25,696			$	2,839				11	%
Epinephrine			26,110				20,091				6,019				30	%
Primatene MIST ®			24,166				23,483				683				3	%
BAQSIMI ®			13,843				-				13,843				N/A
Lidocaine			12,773				13,646				(873	)			(6	)%
Phytonadione			9,973				7,713				2,260				29	%
Enoxaparin			7,096				9,867				(2,771	)			(28	)%
Naloxone			4,287				4,957				(670	)			(14	)%
Other finished pharmaceutical products			29,154				30,557				(1,403	)			(5	)%
Total finished pharmaceutical products net revenues		$	155,937			$	136,010			$	19,927				15	%
API			1,692				4,012				(2,320	)			(58	)%
Other revenues			14,207				-				14,207				N/A
Total net revenues		$	171,836			$	140,022			$	31,814				23	%

Changes in net revenues as compared to the first quarter of the prior year were primarily driven by:

• BAQSIMI ^® sales consisting of $13.8 million in sales made by the Company directly to its customers which are recorded as part of Product Revenues, net, and $24.6 million in sales made by Lilly on behalf of the Company under the Transition Services Agreement ("TSA"), which resulted in a net payment to the Company of $14.2 million after deducting cost of sales and other expenses and was recorded in Other Revenues
• Glucagon sales increased due to a growth in unit volumes, impacting sales by $1.8 million as well as a higher average selling price, impacting sales by $1.1 million as we launched glucagon in Canada
• Epinephrine and Phytonadione sales increased primarily due to an increase in unit volumes, as a result of other supplier shortages
• Primatene MIST ^® sales increased primarily due to an increase in unit volumes and a higher average selling price
• Lidocaine sales decreased primarily due to a decrease in unit volumes, as a result of other suppliers returning to their historical distribution levels
• Enoxaparin and Naloxone sales decreased primarily due to a decrease in unit volumes
• Other finished pharmaceutical product sales changes were primarily due to:
  • Lower unit volumes of MPA, as our Active Pharmaceutical Ingredient ("API") supplier discontinued making the active ingredient
  • This decrease was partially offset by higher unit volumes of dextrose and sodium bicarbonate caused by other supplier shortages during the quarter
  • Launch of regadenoson in April 2023
• API sales decreased primarily due to the timing of customer purchases

		Three Months Ended
		March 31,								Change
		2024				2023				Dollars				%
						(in thousands)
Net revenues		$	171,836			$	140,022			$	31,814			$	23
Cost of revenues			81,736				66,182				15,554				24	%
Gross profit		$	90,100			$	73,840			$	16,260			$	22	%
as % of net revenues			52.4	%			52.7	%

Changes in the cost of revenues and the resulting gross margins were primarily driven by:

• Increase in depreciation and amortization expense related to the acquired BAQSIMI ^® assets
• Increases in labor costs and certain component costs
• Charges included in cost of revenues to adjust our inventory and related purchase commitments to their net realizable value
• These factors were partially offset by increased sales of higher-margin products:
  • BAQSIMI ^® which was acquired in June 2023
  • Glucagon, Primatene MIST ^® , and epinephrine
  • Regadenoson launched in April 2023

		Three Months Ended
		March 31,								Change
		2024				2023				Dollars				%
						(in thousands)
Selling, distribution, and marketing		$	9,371			$	7,109			$	2,262				32	%
General and administrative			15,676				13,483				2,193				16	%
Research and development			17,043				19,815				(2,772	)			(14)	%
Non-operating (expenses) income, net			(134	)			136				(270	)		NM

• Selling, distribution, and marketing expenses increased primarily due to the expansion of our sales and marketing efforts related to BAQSIMI ^®
• General and administrative expenses increased primarily due to an increase in expenses related to BAQSIMI ^®
• Research and development expenses decreased due to the timing of clinical trial expenses, as well as a decrease in materials and supply expenses, primarily related to our insulin and inhalation pipeline products, as a result of a ramp-up in 2023

Cash flow provided by operating activities for the three months ended March 31, 2024, was $55.3 million.

Pipeline Information

The Company currently has four abbreviated new drug applications ("ANDAs") on file with the U.S. Food and Drug Administration (the "FDA") targeting products with a market size of over $3 billion, three biosimilar products in development targeting products with a market size of over $7 billion, and four generic products in development targeting products with a market size of over $3 billion. This market information is based on IQVIA data for the 12 months ended March 31, 2024. The Company is developing multiple proprietary products with injectable and intranasal dosage forms.

Amphastar's Chinese subsidiary, Amphastar Nanjing Pharmaceuticals, Co., Ltd. ("ANP"), currently has multiple Drug Master Files ("DMFs"), on file with the FDA and is developing several additional DMFs.

Company Information

Amphastar is a bio-pharmaceutical company that focuses primarily on developing, manufacturing, marketing, and selling technically-challenging generic and proprietary injectable, inhalation, and intranasal products. Additionally, the Company sells insulin API products. Most of the Company's finished products are used in hospital or urgent care clinical settings and are primarily contracted and distributed through group purchasing organizations and drug wholesalers. More information and resources are available at www.amphastar.com .

Amphastar's logo and other trademarks or service marks of Amphastar, including, but not limited to Amphastar ^® , BAQSIMI ^® , Primatene MIST ^® , REXTOVY ^TM , Amphadase ^® , and Cortrosyn ^® , are the property of Amphastar.

Non-GAAP Financial Measures

To supplement its consolidated financial statements, which are prepared and presented in accordance with U.S. generally accepted accounting principles ("GAAP"), the Company is disclosing non-GAAP financial measures when providing financial results. The Company believes that an evaluation of its ongoing operations (and comparisons of its current operations with historical and future operations) would be difficult if the disclosure of its financial results were limited to financial measures prepared only in accordance with GAAP. As a result, the Company is disclosing certain non-GAAP results, including (i) Adjusted non-GAAP net income (loss) and (ii) Adjusted non-GAAP diluted EPS, which exclude amortization expense, share-based compensation, impairment charges, expenses related to our acquisition of BAQSIMI ^® , certain debt issuance costs, legal settlements, and other one-time events in order to supplement investors' and other readers' understanding and assessment of the Company's financial performance because the Company's management uses these measures internally for forecasting, budgeting, and measuring its operating performance. Whenever the Company uses such non-GAAP measures, it will provide a reconciliation of non-GAAP financial measures to their most directly comparable GAAP financial measures. Investors and other readers are encouraged to review the related GAAP financial measures and the reconciliation of non-GAAP measures to their most directly comparable GAAP measures set forth below and should consider non-GAAP measures only as a supplement to, not as a substitute for or as a superior measure to, measures of financial performance prepared in accordance with GAAP.

Conference Call Information

The Company will hold a conference call to discuss its financial results today, May 8, 2024, at 2:00 p.m. Pacific Time.

To access the conference call, dial toll-free (877) 407-0989 or (201) 389-0921 for international callers, ten minutes before the conference.

The call can also be accessed on the Investors page on the Company's website www.amphastar.com.

Forward Looking Statements

All statements in this press release and in the conference call referenced above that are not historical are forward-looking statements, including, among other things, statements relating to our expectations regarding future financial performance and business trends, our future growth, sales and marketing of our products, market size and expansion, product portfolio, product development, the timing of FDA filings or approvals, including the DMFs of ANP, the timing of product launches, acquisitions and other matters related to our pipeline of product candidates, the timing and results of clinical trials, the prospective benefits of the acquisition of BAQSIMI ^® , including its potential for continued revenue growth, the success of our integration of BAQSIMI ^® , and other future events. These statements are not facts but rather are based on Amphastar's historical performance and our current expectations, estimates, and projections regarding our business, operations, and other similar or related factors. Words such as "may," "might," "will," "could," "would," "should," "anticipate," "predict," "potential," "continue," "expect," "intend," "plan," "project," "believe," "estimate," and other similar or related expressions are used to identify these forward-looking statements, although not all forward-looking statements contain these words. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties, and assumptions that are difficult or impossible to predict and, in some cases, beyond Amphastar's control. Actual results may differ materially from those in the forward-looking statements as a result of a number of factors, including those described in Amphastar's filings with the Securities and Exchange Commission, including in our Annual Report on Form 10-K for the year ended December 31, 2023, filed with the SEC on February 29, 2024. In particular, there can be no guarantee that the acquisition of BAQSIMI ^® will be beneficial to our business, that any event, change or other circumstance could cause the results of the acquisition and integration of BAQSIMI ^® into our product portfolio to differ from Amphastar's expectation, that all or any of the contingent consideration will be payable on the terms described herein or at all, or that Amphastar can reliably predict the impact of BAQSIMI ^® on its financial results or financial guidance. You can locate these reports through our website at http://ir.amphastar.com and on the SEC's website at www.sec.gov. The forward-looking statements in this release speak only as of the date of the release. Amphastar undertakes no obligation to revise or update information or any forward-looking statements in this press release or the conference call referenced above to reflect events or circumstances in the future, even if new information becomes available or if subsequent events cause our expectations to change.

Contact Information:

Amphastar Pharmaceuticals, Inc.
Bill Peters
Chief Financial Officer
(909) 476-3416

Table I
Amphastar Pharmaceuticals, Inc.
Condensed Consolidated Statement of Operations
(Unaudited; in thousands, except per share data)

		Three Months Ended
		March 31,
		2024				2023
Net revenues:
Product revenues, net		$	157,629			$	140,022
Other revenues			14,207				-
Total net revenues			171,836				140,022
Cost of revenues			81,736				66,182
Gross profit			90,100				73,840
Operating expenses:
Selling, distribution, and marketing			9,371				7,109
General and administrative			15,676				13,483
Research and development			17,043				19,815
Total operating expenses			42,090				40,407
Income from operations			48,010				33,433
Non-operating (expenses) income, net			(134	)			136
Income before income taxes			47,876				33,569
Income tax provision			4,126				6,752
Net income before equity in losses of unconsolidated affiliate			43,750				26,817
Equity in losses of unconsolidated affiliate			(573	)			(785	)
Net income		$	43,177			$	26,032
Net income per share:
Basic		$	0.90			$	0.54
Diluted		$	0.81			$	0.50
Weighted-average shares used to compute net income per share:
Basic			48,212				48,000
Diluted			53,013				51,970

Table II
Amphastar Pharmaceuticals, Inc.
Condensed Consolidated Balance Sheet
(Unaudited; in thousands, except per share data)

		March 31,				December 31,
		2024				2023
		(unaudited)
ASSETS
Current assets:
Cash and cash equivalents		$	201,148			$	144,296
Restricted cash			235				235
Short-term investments			88,407				112,510
Restricted short-term investments			2,200				2,200
Accounts receivable, net			138,114				114,943
Inventories			115,494				105,833
Income tax refunds and deposits			784				526
Prepaid expenses and other assets			8,696				9,057
Total current assets			555,078				489,600
Property, plant, and equipment, net			288,523				282,746
Finance lease right-of-use assets			516				564
Operating lease right-of-use assets			31,352				32,333
Investment in unconsolidated affiliate			-				527
Goodwill and intangible assets, net			607,064				613,295
Long-term investments			15,163				14,685
Other assets			23,369				25,910
Deferred tax assets			53,252				53,252
Total assets		$	1,574,317			$	1,512,912
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
Accounts payable and accrued liabilities		$	116,697			$	93,366
Accrued payments for BAQSIMI ®			128,245				126,090
Income taxes payable			5,857				1,609
Current portion of long-term debt			428				436
Current portion of operating lease liabilities			3,942				3,906
Total current liabilities			255,169				225,407
Long-term reserve for income tax liabilities			6,066				6,066
Long-term debt, net of current portion and unamortized debt issuance costs			594,006				589,579
Long-term operating lease liabilities, net of current portion			28,739				29,721
Other long-term liabilities			17,981				22,718
Total liabilities			901,961				873,491
Commitments and contingencies
Stockholders' equity:
Preferred stock: par value $0.0001; 20,000,000 shares authorized; no shares issued and outstanding			-				-
Common stock: par value $0.0001; 300,000,000 shares authorized; 60,160,459 and 48,841,343 shares issued and outstanding as of March 31, 2024 and 59,390,194 and 48,068,881 shares issued and outstanding as of December 31, 2023, respectively			6				6
Additional paid-in capital			476,072				486,056
Retained earnings			452,445				409,268
Accumulated other comprehensive loss			(8,769	)			(8,478	)
Treasury stock			(247,398	)			(247,431	)
Total equity			672,356				639,421
Total liabilities and stockholders' equity		$	1,574,317			$	1,512,912

Table III
Amphastar Pharmaceuticals, Inc.
Reconciliation of Non-GAAP Measures
(Unaudited; in thousands, except per share data)

		Three Months Ended
		March 31,
		2024				2023
GAAP net income		$	43,177			$	26,032
Adjusted for:
Intangible asset amortization			6,167				241
Share-based compensation			7,360				6,111
Expenses related to BAQSIMI ® acquisition			1,826				1,217
Income tax provision on pre-tax adjustments			(3,234	)			(1,458	)
Adjusted non-GAAP net income		$	55,296			$	32,143
Adjusted non-GAAP net income per share:
Basic		$	1.15			$	0.67
Diluted		$	1.04			$	0.62
Weighted-average shares used to compute adjusted non-GAAP net income per share:
Basic			48,212				48,000
Diluted			53,013				51,970

		Three Months Ended March 31, 2024
		Cost of revenue				Selling, distribution and marketing				General and administrative				Research and development				Non-operating (expenses) income, net				Income tax provision
GAAP		$	81,736			$	9,371			$	15,676			$	17,043			$	(134	)		$	4,126
Intangible asset amortization			(6,147	)			-				(3	)			(17	)			-				-
Share-based compensation			(2,125	)			(260	)			(3,876	)			(1,099	)			-				-
Expenses related to BAQSIMI ® acquisition			-				-				-				-				1,826				-
Income tax provision on pre-tax adjustments			-				-				-				-				-				3,234
Non-GAAP		$	73,464			$	9,111			$	11,797			$	15,927			$	1,692			$	7,360

		Three Months Ended March 31, 2023
		Cost of revenue				Selling, distribution and marketing				General and administrative				Research and development				Non-operating (expenses) income, net				Income tax provision
GAAP		$	66,182			$	7,109			$	13,483			$	19,815			$	136			$	6,752
Intangible asset amortization			(211	)			-				(30	)			-				-				-
Share-based compensation			(1,706	)			(209	)			(3,357	)			(839	)			-				-
Expenses related to BAQSIMI ® acquisition			-				-				(1,217	)			-				-				-
Income tax provision on pre-tax adjustments			-				-				-				-				-				1,458
Non-GAAP		$	64,265			$	6,900			$	8,879			$	18,976			$	136			$	8,210

SOURCE: Amphastar Pharmaceuticals, Inc.

View the original press release on accesswire.com

FAQ

What were Amphastar Pharmaceuticals' net revenues for the three months ended March 31, 2024?

Amphastar Pharmaceuticals reported net revenues of $171.8 million for the three months ended March 31, 2024.

What was the GAAP net income for Amphastar Pharmaceuticals in the first quarter of 2024?

Amphastar Pharmaceuticals achieved GAAP net income of $43.2 million for the first quarter of 2024.

Which products contributed to Amphastar Pharmaceuticals' revenue growth?

Products like Glucagon, Epinephrine, and Primatene MIST ® contributed to revenue growth for Amphastar Pharmaceuticals.

What was the gross profit margin of Amphastar Pharmaceuticals for the first quarter of 2024?

Amphastar Pharmaceuticals maintained a gross profit margin of 52.4% of net revenues for the first quarter of 2024.

What financial measure excludes certain expenses to supplement investors' understanding of Amphastar Pharmaceuticals' performance?

Adjusted non-GAAP net income and Adjusted non-GAAP diluted EPS are non-GAAP financial measures used by Amphastar Pharmaceuticals to supplement investors' understanding of the company's performance.